Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 6

Management of L-dopa overdose in the competitive inhibition state

Authors Hinz M, Stein A, Cole T

Received 7 May 2014

Accepted for publication 22 May 2014

Published 22 July 2014 Volume 2014:6 Pages 93—99

DOI https://doi.org/10.2147/DHPS.S67328

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Marty Hinz,1 Alvin Stein,2 Ted Cole3

1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Cole Center for Healing, Cincinnati, OH, USA

Abstract: The amino acid L-3,4-dihydroxyphenylalanine (L-dopa) is prescribed for conditions where increased central and/or peripheral dopamine synthesis is desired. Its administration can establish dopamine concentrations higher than can be achieved from an optimal diet. Specific indications include Parkinson's disease and restless leg syndrome. The interaction between serotonin and dopamine exists in one of two distinctly different physiologic states: the endogenous state or the competitive inhibition state. Management with L-dopa in the competitive inhibition state is the focus of this paper. In the past, control of the competitive inhibition state was thought to be so difficult and complex that it was described in the literature as functionally “meaningless”. When administering L-dopa without simultaneous administration of serotonin precursors, the patient is in the endogenous state. Experience gained with patient outcomes during endogenous L-dopa administration does not allow predictability of L-dopa outcomes in the competitive inhibition state. The endogenous approach typically increases the daily L-dopa dosing value in a linear fashion until symptoms of Parkinson's disease are under control. It is the novel observations made during treatment with the competitive inhibition state approach that L-dopa dosing values above or below the optimal therapeutic range are generally associated with the presence of the exact same Parkinson's disease symptoms with identical intensity. This recognition requires a novel approach to optimization of daily L-dopa dosing values from that used in the endogenous state. This paper outlines that novel approach through utilization of a pill stop. This approach enhances patient safety through its ability to prevent L-dopa overdose, while assisting in the establishment of the optimal therapeutic L-dopa daily dosing value.

Keywords: L-3,4-dihydroxyphenylalanine, L-dopa, levodopa, Parkinson's disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Parkinson's disease managing reversible neurodegeneration [Corrigendum]

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:1587-1588

Published Date: 28 June 2016

Amino acid management of Parkinson's disease: a case study [Corrigendum]

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2016, 9:205-206

Published Date: 13 June 2016

Parkinson’s disease managing reversible neurodegeneration

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:763-775

Published Date: 5 April 2016

Relative nutritional deficiencies associated with centrally acting monoamines [Corrigendum]

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2015, 8:163-164

Published Date: 22 April 2015

Parkinson’s disease-associated melanin steal

Hinz M, Stein A, Cole T

Neuropsychiatric Disease and Treatment 2014, 10:2331-2337

Published Date: 10 December 2014

Parkinson's disease: carbidopa, nausea, and dyskinesia

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:189-194

Published Date: 14 November 2014

The Parkinson's disease death rate: carbidopa and vitamin B6

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:161-169

Published Date: 21 October 2014

Administration of supplemental L-tyrosine with phenelzine: a clinical literature review

Hinz M, Stein A, Cole T, Ryan P

Clinical Pharmacology: Advances and Applications 2014, 6:107-110

Published Date: 22 July 2014

5-HTP efficacy and contraindications

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2012, 8:323-328

Published Date: 19 July 2012

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

The discrediting of the monoamine hypothesis

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:135-142

Published Date: 14 February 2012

Monoamine depletion by reuptake inhibitors

Hinz M, Stein A, Uncini T

Drug, Healthcare and Patient Safety 2011, 3:69-77

Published Date: 20 October 2011

APRESS: apical regulatory super system, serotonin, and dopamine interaction

Hinz M, Stein A, Uncini T

Neuropsychiatric Disease and Treatment 2011, 7:457-463

Published Date: 5 August 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine

Marty Hinz, Alvin Stein, Thomas Uncini

Research and Reports in Urology 2011, 3:19-24

Published Date: 4 February 2011

Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation

Marty Hinz, Alvin Stein, Robert Neff, et al

Neuropsychiatric Disease and Treatment 2011, 7:31-38

Published Date: 26 January 2011

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:741-747

Published Date: 9 November 2010

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

The dual-gate lumen model of renal monoamine transport

Marty Hinz, Alvin Stein, Thomas Uncini

Neuropsychiatric Disease and Treatment 2010, 6:387-392

Published Date: 5 July 2010

Readers of this article also read:

Parkinson’s disease managing reversible neurodegeneration

Hinz M, Stein A, Cole T, McDougall B, Westaway M

Neuropsychiatric Disease and Treatment 2016, 12:763-775

Published Date: 5 April 2016

Parkinson's disease: carbidopa, nausea, and dyskinesia

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:189-194

Published Date: 14 November 2014

The Parkinson's disease death rate: carbidopa and vitamin B6

Hinz M, Stein A, Cole T

Clinical Pharmacology: Advances and Applications 2014, 6:161-169

Published Date: 21 October 2014

Oral available agents in the treatment of RRMS

Aupérin T

Drug, Healthcare and Patient Safety 2013, 5:199-201

Published Date: 29 October 2013

Specific safety and tolerability considerations in the use of anticonvulsant medications in children

Crepeau A, Moseley BD, Wirrell EC

Drug, Healthcare and Patient Safety 2012, 4:39-54

Published Date: 6 June 2012

Relative nutritional deficiencies associated with centrally acting monoamines

Hinz M, Stein A, Uncini T

International Journal of General Medicine 2012, 5:413-430

Published Date: 8 May 2012

Monoamine depletion by reuptake inhibitors

Hinz M, Stein A, Uncini T

Drug, Healthcare and Patient Safety 2011, 3:69-77

Published Date: 20 October 2011

Amino acid management of Parkinson’s disease: a case study

Marty Hinz, Alvin Stein, Thomas Uncini

International Journal of General Medicine 2011, 4:165-174

Published Date: 28 February 2011

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010